// App-Quantinova.ai

e19056 : Differences between Japan and rest of world (ROW) in disease presentation and outcome of previously treated adult t-cell leukemia-lymphoma (ATL) using therapy with a monoclonal antibody to CCR4, mogamulizumab (moga).

Researchers

Presenter

  • Adrienne Alise Phillips

Principal Investigators

  • Steven M. Horwitz

  • Graham P. Taylor

  • Jeffrey S. Humphrey

  • Kensei Tobinai

  • Takashi Ishida

  • Ryuzo Ueda

Medical Centers

  • New York Presbyterian Weill Cornell Medical Center, New York, NY

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Imperial College, London, United Kingdom

  • Kyowa Kirin Pharmaceutical Development, Inc., Princeton, NJ

  • National Cancer Center Hospital, Tokyo, Japan

  • Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

  • Aichi Medical University School of Medicine, Nagakute, Japan

Locations

  • United States

  • United Kingdom

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Adult T-Cell Leukemia

Biomarkers

  • C-C Motif Chemokine Receptor 4

Drug/Treatment

  • Mogamulizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01626664

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved